{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:34:21Z","timestamp":1788813261170,"version":"build-2803163510"},"reference-count":55,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019718","name":"Boehringer Ingelheim Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To report two phase I studies of the novel subcutaneous glucagon\u2010like peptide\u20101 receptor\/glucagon receptor (GLP\u20101R\/GCGR) dual agonist BI 456906 versus placebo in healthy volunteers and people with overweight\/obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      A phase Ia study (NCT03175211) investigated single rising doses (SRDs) of BI 456906 in 24 males with a body mass index (BMI) of 20\u2013&lt;30\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . A phase Ib study (NCT03591718) investigated multiple rising doses (MRDs) of BI 456906 (escalated over 6 [Part A] or 16 [Part B] weeks) in 125 adults with a BMI of 27\u201340\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the SRD study (N\u00a0=\u00a024), mean body weight decreased with increasing BI 456906 dose. In the MRD study, the maximum decreases in placebo\u2010corrected mean body weight were at week 6 (\u20135.79%, dosage schedule [DS] 1; Part A) and week 16 (\u201313.8%, DS7; Part B). BI 456906 reduced plasma amino acids and glucagon, indicating target engagement at GCGRs and GLP\u20101Rs. Drug\u2010related adverse events (AEs) increased with BI 456906 dose. The most frequent drug\u2010related AE with SRDs was decreased appetite (n\u00a0=\u00a09, 50.0%), and two subjects (8.3%) did not complete the trial because of AEs (nausea and vomiting). During MRD Part A (N\u00a0=\u00a080), 10 subjects (12.5%) discontinued BI 456906, most commonly because of a cardiac or vascular AE (n\u00a0=\u00a06, 7.5%); during Part B (N\u00a0=\u00a045), eight subjects (17.8%) discontinued BI 456906, mainly because of AEs (n\u00a0=\u00a06, 13.3%), most commonly gastrointestinal disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>BI 456906 produced a placebo\u2010corrected body weight loss of 13.8% (week 16), highlighting its potential to promote clinically meaningful body weight loss in people with overweight\/obesity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.14948","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T08:20:38Z","timestamp":1671265238000},"page":"1011-1023","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor\/glucagon\u2010like peptide\u20101 receptor agonist\n                    <scp>BI<\/scp>\n                    456906"],"prefix":"10.1111","volume":"25","author":[{"given":"Arvid","family":"Jungnik","sequence":"first","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH  Biberach Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5926-9472","authenticated-orcid":false,"given":"Jorge","family":"Arrubla Martinez","sequence":"additional","affiliation":[{"name":"Profil Institute for Metabolic Research  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1907-761X","authenticated-orcid":false,"given":"Leona","family":"Plum\u2010M\u00f6rschel","sequence":"additional","affiliation":[{"name":"Profil Mainz GmbH &amp; Co. KG  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9700-2373","authenticated-orcid":false,"given":"Christoph","family":"Kapitza","sequence":"additional","affiliation":[{"name":"Profil Institute for Metabolic Research  Neuss Germany"},{"name":"Profil Mainz GmbH &amp; Co. KG  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Lamers","sequence":"additional","affiliation":[{"name":"Profil Institute for Metabolic Research  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Thamer","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH  Biberach Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Sch\u00f6lch","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH  Biberach Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0205-1592","authenticated-orcid":false,"given":"Michael","family":"Desch","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH  Biberach Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita M.","family":"Hennige","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH  Biberach Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00337-8"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1514957"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00145-5"},{"issue":"2","key":"e_1_2_9_5_1","doi-asserted-by":"crossref","first-page":"e13372","DOI":"10.1111\/obr.13372","article-title":"The incretin\/glucagon system as a target for pharmacotherapy of obesity","volume":"23","author":"Del Prato S","year":"2021","journal-title":"Obes Rev."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0118-x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.7602"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2020.1698291"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.11.011"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13399"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2011.158"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_2_9_13_1","volume-title":"Prescribing Information","author":"Liraglutide (Saxenda)","year":"2020"},{"key":"e_1_2_9_14_1","volume-title":"Prescribing Information","author":"Orlistat (Xenical)","year":"2017"},{"key":"e_1_2_9_15_1","volume-title":"Prescribing Information","author":"Naltrexone\/Bupropion ER (Contrave)","year":"2019"},{"key":"e_1_2_9_16_1","volume-title":"(Qsymia) Prescribing Information","author":"Phentermine\/Topiramate ER","year":"2018"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00013.2014"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00492.2002"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-1878-0"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2012.227"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.00413"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2019.110696"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/db12-0797"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12585"},{"issue":"1","key":"e_1_2_9_25_1","first-page":"R116","article-title":"Glucagon acts in the liver to control spontaneous meal size in rats","volume":"264","author":"Geary N","year":"1993","journal-title":"Am J Physiol."},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1740-0929.2009.00685.x"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12464"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-014-9289-5"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.01.09"},{"key":"e_1_2_9_30_1","unstructured":"U.S. Food & Drug Administration.FDA approves new drug treatment for chronic weight management.2014.https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-treatment-chronic-weight-management-first-2014. Accessed November 4 2022."},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2017.09.018"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00576.2007"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2003-1338"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.8.2390"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0803344"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2012.67"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12735"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2151"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186586"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101088"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101691"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14110"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101633"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-349-10705-6_16"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2020.0258"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1705277"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14496"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15638"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0803175"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0668-z"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002208"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14373"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14280"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hjc.2018.11.008"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01707-4"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14948","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14948","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14948","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:47:26Z","timestamp":1761875246000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1111\/dom.14948"],"URL":"https:\/\/doi.org\/10.1111\/dom.14948","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.14948\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14948\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14948\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14948\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14948\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14948\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14948\/v1\/review3","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,30]]},"assertion":[{"value":"2022-10-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}